DETAIL 2004

Methods	Country: USA Setting/Design: Multicentre Time frame: NS Randomisation method: Central location‐based on permuted blocks Blinding ‐ Participants: Yes ‐ Investigators: Yes ‐ Outcome assessors: No ‐ Data analysis: No Intention‐to‐treat: No Follow‐up period: 5 years Loss to follow‐up: 2
Participants	Inclusion criteria Age: 35‐80 years DM: Type 2 treated by diet, diet plus oral hypoglycaemic drugs (for at least 1 year), or insulin preceded by treatment with oral agents (also for at least 1 year). Among those whose diabetes was treated with insulin, the onset of diabetes had to have occurred after the age of 40 and the BMI had to be more than 25 at the time of diagnosis Hypertension: Mild to moderate with a resting BP < 180/95 mm Hg after at least 3 months of ACEi therapy before entry into the study Renal morphology: Normal UAE: Mean of 3 consecutive overnight values between 11 and 999 µg/min with 2 values > 10 μg/min HbA1c: < 12 SCr: < 1.6 mg/dL GFR: > 70 mL/min/1.73 m² Enalapril group Number: 130 Age: 60.0 (9.1) Sex (M/F): 95/35 Telmiosartan group Number: 120 Age: 61.2 (8.5) Sex (M/F): 87/33 Exclusion criteria Any condition (other than cardiovascular disease) that could restrict long‐term survival and known allergy to study drugs or iohexol
Interventions	Enalapril group 20 mg/d Telmiosartan group 80 mg/d Co‐interventions Others antihypertensive agents (except ACEi or AIRA) were allowed after 2 months.
Outcomes	Changes in GFR UAE SCr BP The rates of clinical events (ESKD, MI, stroke, CHF) Rate of death from all causes Rate of adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate